OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Investigational Drugs is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	86
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	85
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	81
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	76
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	76
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	75
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	64
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	62
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	56
Theranostic strategies in sarcoma: preliminary clinical evidence	44
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	43
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	39
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	36
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	34
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	33
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	31
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	30
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	29
Emerging treatments for chronic urticaria	27
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	26
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	26
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	22
Investigational drugs for the treatment of dysmenorrhea	22
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	22

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	22
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	22
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	21
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	20
Investigational drugs for immune thrombocytopenia	19
Potassium channel modulators and schizophrenia: an overview of investigational drugs	19
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	19
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	18
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer	18
Current options and investigational drugs for the treatment of eosinophilic esophagitis	18
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	18
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	18
Recent developments in adjunct therapies for type 1 diabetes	18
Frontotemporal dementia: from genetics to therapeutic approaches	17
IgA nephropathy: an overview of drug treatments in clinical trials	17
What is the progress of experimental drug development for fibromyalgia?	16
Investigational new drugs for the treatment of leishmaniasis	16
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	16
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	15
Novel systemic treatment approaches for metastatic pancreatic cancer	15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	15
NF1 alterations in cancers: therapeutic implications in precision medicine	15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	15
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	15
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	15
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	15
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	15
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	15
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	15
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021	14
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions	14
Assessing the clinical progress of the bispecific nanobody sonelokimab	14
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	14
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	12
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	12
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials	12
Clinical development of tri-specific antibodies for immune-oncology	12
Investigational drugs for the treatment of olfactory dysfunction	12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	12
Investigational thrombolytic drugs for acute ischemic stroke	12
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	12
Navafenterol for chronic obstructive pulmonary disease therapy	12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	12
JAK inhibitors for rheumatoid arthritis	12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?	12

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	12
JAK inhibitors in crohn’s disease: ready to go?	11
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	11
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights	11
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	11
Immunotherapeutic strategies for treating opioid use disorder and overdose	11
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	11
Camrelizumab: an investigational agent for hepatocellular carcinoma	11
Investigational new drugs for the treatment of Dravet syndrome: an update	11
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	11
An update on novel investigational agents for the treatment of primary biliary cholangitis	11
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	11
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	10
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	10
Inflammation and Huntington’s disease – a neglected therapeutic target?	10
Assessing potential of psilocybin for depressive disorders	10
Prospects of current AXL-targeting therapies in early phase cancer trials	10
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials	10
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	10
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	10
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs	10
The impact of current investigational drugs for acne on future treatment strategies	10
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	10
Investigational anti IL-13 asthma treatments: a 2023 update	10
IRAK signaling in cancers: mechanisms, targeting, and clinical implications	10
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	10
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	10
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	10
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	10
Preclinical prospects of investigational agents for hearing loss treatment	10